# Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study

> **NCT00291343** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 296 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Tritanrix™- HepB
- **BIOLOGICAL:** Hiberix™
- **BIOLOGICAL:** Mencevax™ ACWY

## Key facts

- **NCT ID:** NCT00291343
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02-01
- **Primary completion:** 2007-03-15
- **Final completion:** 2007-03-15
- **Target enrollment:** 296 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291343, "Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00291343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*